Recently in melanoma, elevated G9a levels promoted cancer progression through the activation of the WNT/β-catenin signaling by epigenetic silencing of the WNT antagonist DKK1 gene [165], or through the upregulation of the Notch1 signaling pathway, that further stimulates PI3K/AKT pathway [119]. The gene discussed is EHMT2; the disease is melanoma.